— Protheragen, an ISO9001 certified supplier of pharmaceutical ingredients and specialty chemicals, announces its expanded suite of end-to-end impurity solutions covering impurity synthesis & isolation, forced degradation impurity profiling, and the supply of high-purity drug impurity reference standards, supporting pharmaceutical developers worldwide in enhancing drug safety, efficacy, and regulatory compliance.
In drug development and manufacturing, precise identification, rigorous control, and thorough characterization of impurities are critical to mitigating safety risks and meeting stringent regulatory requirements. Trace-level impurities, including genotoxic impurities, process byproducts, and degradation species, remain under intense scrutiny by global health authorities. Protheragen addresses these challenges with integrated platforms and customized services designed to deliver reliable, compliant data, and high-quality reference materials.
A core pillar of Protheragen’s offering is impurity synthesis & isolation, supporting clients from initial molecular design through to the delivery of purified samples. Protheragen’s experts specialize in complex organic synthesis, chiral impurity construction, genotoxic impurity (GTI) preparation, degradation impurity generation, process-related byproduct replication, and isotope-labeled impurity synthesis. Using advanced technologies such as preparative HPLC (Prep-HPLC) and supercritical fluid chromatography (SFC), Protheragen’s expert team isolates high-purity impurities from complex matrices, supporting analytical method development, validation, and toxicological studies across milligram to gram scales.
Complementing synthetic capabilities, Protheragen delivers robust forced degradation impurity analysis to evaluate drug stability under stress conditions, including hydrolytic, oxidative, photolytic, and thermal degradation. Using HPLC, LC-MS, NMR, and other high-end instruments, Protheragen identifies, characterizes, and quantifies forced degradation impurity profiles, revealing degradation pathways and supporting evidence-based packaging, storage, and shelf-life recommendations. These studies help predict real-world stability, reduce development risks, and accelerate regulatory submissions.
Central to these services is the consistent delivery of high-quality drug impurity reference standards, which underpin accurate qualitative and quantitative impurity testing. Protheragen’s separation and purification platforms resolve challenging chiral and achiral separations, enrich trace impurities, and produce highly pure reference materials complete with comprehensive characterization data—including structural elucidation, analytical certificates, and full experimental records—to meet global regulatory expectations.
“We combine scientific expertise, world-class platforms, and strict quality management to solve the most complex impurity challenges for our partners,” said a representative of Protheragen Impurity. “By advancing impurity synthesis & isolation, forced degradation impurity studies, and the supply of certified drug impurity reference standards, we help pharmaceutical developers enhance product safety, streamline compliance, and bring reliable therapies to patients faster.”
Protheragen operates integrated synthetic chemistry, separation-purification, and analytical-characterization platforms, staffed by experienced chemists and analytical experts adhering to ISO-based quality standards. In addition to tailored solutions, Protheragen also provides in-stock impurity products adaptable to diverse project scales and demands, serving as a long-term partner for impurity control across the entire drug development lifecycle.
About Protheragen
Protheragen is a leading global service provider dedicated to impurity research for the pharmaceutical industry. Offering customized solutions spanning impurity identification, impurity synthesis & isolation, forced degradation impurity analysis, genotoxicity risk assessment, residual solvent and elemental impurity testing, and high-purity impurity products, the company supports drug developers in ensuring safety, efficacy, and compliance throughout development and commercialization.
Contact Info:
Name: Hannah Green
Email: Send Email
Organization: Protheragen
Website: https://www.protheragen.ai/
Release ID: 89189523
If you detect any issues, problems, or errors in this press release content, kindly contact error@releasecontact.com to notify us (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). We will respond and rectify the situation in the next 8 hours.